Displaying items by tag: cystic fibrosis

After a series of breakthroughs that researcher Steven Rowe calls "one of the most remarkable stories in modern medicine," the majority of patients with cystic fibrosis can now be treated with highly effective therapies. The next step: adapting these treatments to COPD, asthma and a host of other conditions.
A two-drug combination therapy for cystic fibrosis is shown to be effective. Triple combination therapy is close behind.
Successful Phase III trials at UAB contributed to the development of a novel “corrector-potentiator” combination drug therapy for cystic fibrosis patients.
UAB and UMass researchers have uncovered a new mechanistic understanding of potential treatment for genetic disorders.
Cystic fibrosis lung cells were restored to 50 percent of healthy function in work that provides the first evidence that novel therapeutic strategies for human patients can be identified based on yeast studies.
Southern Research and UAB launch a search for compounds that might provide new therapies for CF nonsense mutations.
The Cystic Fibrosis Foundation recognizes UAB’s Adult CF Program with Quality Care Award.
UAB was part of a promising international study of a combination therapy for patients with the most common cystic fibrosis mutation.

UAB researchers find spiritual coping a predictor of mental health in chronically ill youth; recommend clinicians assess spirituality.